ERBB2 and breast carcinoma: Additionally, our study offers a detailed assessment of the predictive performance of the HFA-ICOS risk assessment tool, including a meta-analysis of its performance in patients with breast cancer receiving HER2 targeted therapies, further advancing the understanding of its prognostic value.